BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36164267)

  • 1. Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis.
    Sharpton SR; Oh TG; Madamba E; Wang C; Yu RT; Atkins AR; Huan T; Downes M; Evans RM; Loomba R
    Aliment Pharmacol Ther; 2022 Nov; 56(10):1475-1485. PubMed ID: 36164267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hip Fractures in Patients With Liver Cirrhosis: Worsening Liver Function Is Associated with Increased Mortality.
    Hundersmarck D; Groot OQ; Schuijt HJ; Hietbrink F; Leenen LPH; Heng M
    Clin Orthop Relat Res; 2022 Jun; 480(6):1077-1088. PubMed ID: 34978539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
    Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
    J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
    Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
    Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.
    Praktiknjo M; Simón-Talero M; Römer J; Roccarina D; Martínez J; Lampichler K; Baiges A; Low G; Llop E; Maurer MH; Zipprich A; Triolo M; Maleux G; Fialla AD; Dam C; Vidal-González J; Majumdar A; Picón C; Toth D; Darnell A; Abraldes JG; López M; Jansen C; Chang J; Schierwagen R; Uschner F; Kukuk G; Meyer C; Thomas D; Wolter K; Strassburg CP; Laleman W; La Mura V; Ripoll C; Berzigotti A; Calleja JL; Tandon P; Hernandez-Gea V; Reiberger T; Albillos A; Tsochatzis EA; Krag A; Genescà J; Trebicka J;
    J Hepatol; 2020 Jun; 72(6):1140-1150. PubMed ID: 31954206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.
    Oh TG; Kim SM; Caussy C; Fu T; Guo J; Bassirian S; Singh S; Madamba EV; Bettencourt R; Richards L; Yu RT; Atkins AR; Huan T; Brenner DA; Sirlin CB; Downes M; Evans RM; Loomba R
    Cell Metab; 2020 Nov; 32(5):878-888.e6. PubMed ID: 32610095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis.
    Calzadilla-Bertot L; Vilar-Gomez E; Wong VW; Romero-Gomez M; Aller-de la Fuente R; Wong GL; Castellanos M; Eslam M; Desai AP; Jeffrey GP; George J; Chalasani N; Adams LA
    Hepatology; 2021 Jun; 73(6):2238-2250. PubMed ID: 32978796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis.
    Tapper EB; Aberasturi D; Zhao Z; Hsu CY; Parikh ND
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1397-1405. PubMed ID: 32363684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Machine Learning-based Development and Validation of a Scoring System for Screening High-Risk Esophageal Varices.
    Dong TS; Kalani A; Aby ES; Le L; Luu K; Hauer M; Kamath R; Lindor KD; Tabibian JH
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1894-1901.e1. PubMed ID: 30708109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study.
    Kim BK; Bergstrom J; Loomba R; Tamaki N; Izumi N; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Truong E; Yang JD; Noureddin M; Allen AM; Loomba R; Ajmera V
    Hepatology; 2023 Dec; 78(6):1858-1866. PubMed ID: 37203233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk assessment of development of hepatic decompensation in histologically proven hepatitis B viral cirrhosis using liver stiffness measurement.
    Kim BK; Park YN; Kim DY; Park JY; Chon CY; Han KH; Ahn SH
    Digestion; 2012; 85(3):219-27. PubMed ID: 22414567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.
    Han MAT; Vipani A; Noureddin N; Ramirez K; Gornbein J; Saouaf R; Baniesh N; Cummings-John O; Okubote T; Setiawan VW; Rotman Y; Loomba R; Alkhouri N; Noureddin M
    Liver Int; 2020 Sep; 40(9):2242-2251. PubMed ID: 32652744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with liver cirrhosis show worse survival if decompensation occurs later during course of disease than at diagnosis.
    Nilsson E; Anderson H; Sargenti K; Lindgren S; Prytz H
    Scand J Gastroenterol; 2018 Apr; 53(4):475-481. PubMed ID: 29513096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of magnetic resonance elastography in compensated and decompensated liver disease.
    Asrani SK; Talwalkar JA; Kamath PS; Shah VH; Saracino G; Jennings L; Gross JB; Venkatesh S; Ehman RL
    J Hepatol; 2014 May; 60(5):934-9. PubMed ID: 24362072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.
    Loomba R; Seguritan V; Li W; Long T; Klitgord N; Bhatt A; Dulai PS; Caussy C; Bettencourt R; Highlander SK; Jones MB; Sirlin CB; Schnabl B; Brinkac L; Schork N; Chen CH; Brenner DA; Biggs W; Yooseph S; Venter JC; Nelson KE
    Cell Metab; 2017 May; 25(5):1054-1062.e5. PubMed ID: 28467925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis.
    Liu TL; Trogdon J; Weinberger M; Fried B; Barritt AS
    Dig Dis Sci; 2016 Nov; 61(11):3335-3345. PubMed ID: 27480088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
    Bajaj JS
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the Risk of Further Decompensation and Survival in Patients With Cirrhosis With Variceal Bleeding as Their First Decompensation Event.
    Gupta A; Rana R; Agarwal S; Sharma S; Gopi S; Mohta S; Gunjan D; Saraya A
    Am J Gastroenterol; 2023 May; 118(5):833-839. PubMed ID: 36114777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.
    Simon TG; Patorno E; Schneeweiss S
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1382-1393.e19. PubMed ID: 34256144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
    Higuera-de-la-Tijera F; Servín-Caamaño AI; Salas-Gordillo F; Pérez-Hernández JL; Abdo-Francis JM; Camacho-Aguilera J; Alla SN; Jiménez-Ponce F
    Can J Gastroenterol Hepatol; 2018; 2018():3015891. PubMed ID: 30079329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.